ד"ר אורי בריטברד

2006- 2010                  Post-Doctoral fellow, Dept. of Cell and Developmental Biology, Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Israel.

                                    Supervisor: Prof. Jacob Hochman

                                    Research interests:  1. Developing novel approaches toward reversal of multi-drug resistance in cancer.  2. Vaccination against breast cancer.

2001- 2005                  Ph.D., Dept. of Biological Chemistry, Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Israel.

                                    Supervisors: Prof. Wilfred D. Stein and Prof. Deborah Rund.

                                    Research Title: 

                                    Characterization of proteins that are involved in resistance to chemotherapy in different kinds of leukemia

1999-2000                   M.Sc., Dept. of Biological Chemistry, Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Israel.

                                    Supervisor: Prof. Wilfred D. Stein

Thesis Title: Methods to estimate the amount and cost of production of P-   glycoprotein from different sources of membranes.

1996-99                       B.Sc. Degree in Biology, Faculty of Life Sciences, Bar Ilan University, Ramat Gan, Israel.

1992-95                       Senior Teacher Degree in Bible and Gmara, The E.M. Liphshitz     Religious Teachers College, Kiryat Shmona (the northern branch), Israel.

Peer-Reviewed Papers in Refereed Journals

1. Ori Braitbard, Janette Bishara-Shieban, Hava Glickstein, Miriam Kott-Gutkowski Umberto Pace, Deborah G. Rund and Wilfred D. Stein .

 An ELISA-based procedure for assaying proteins in digests of human lymphocytes and cell lines, using specifically chosen peptides and appropriate antibodies. 

      Proteome Science 2006, 4:14, 1-11

    Impact Factor: 1.73  Cited by 1  Rank: Q2.

2. Ori Braitbard, Hava Glickstein, Janette Bishara-Shieban, Umberto Pace, Wilfred D. Stein .

Competition between bound and free peptides in an ELISA-based procedure that assays peptides derived from protein digests

Proteome Science  2006, 4:12 , 1-12

    Impact Factor: 1.73   Cited by 6  Rank: Q2.

3. Uziel Sandler, Orly Devary, Ori Braitbard, Joel Ohana, Gideon Kass, Ariel M. Rubinstein, Zeev Y. Friedman and Yoram Devary

     NEROFE™ - A novel human hormone-peptide with anti-cancer activity

Journal of Experimental Therapeutics and Oncology. Volume 8, Number 4, 2010, p. 327-339.

Cited by 1 Rank: Q3

4. Cesar M. Manna, Ori Braitbard, Esther Weiss-Lavi, Jacob Hochman, and Edit Y. Tshuva . Salan-Ti(IV) Complexes are Highly Robust and Highly Active Towards A Range of Sensitive and Drug Resistant Cell Lines

ChemMedChem.  2012 Apr;7(4):703-8.

Impact Factor: 2.968  Cited by 34  Rank: Q1

5. Reytman L, Braitbard O, Tshuva EY. Dalton Trans. 2012 May 7;41(17):5241-7.

     Highly cytotoxic vanadium(V) complexes of salan ligands; insights on the role of hydrolysis.

Impact Factor 4.197  Cited by 39  Rank: Q1

6. Wellhöner H, Weiss A, Schulz A, Adermann K, Braitbard O, Bar-Sinai A, Hochman J. Reversing ABCB1-mediated multi-drug resistance from within cells using translocating immune conjugates.

J Drug Target. 2012 Jun;20(5):445-52.                                                                 

     Impact Factor: 2.741 Cited by 5  Rank: Q1

7. Feldman, D., Roniger, M., Bar-Sinai, A., Braitbard, O., Rajchman, D., Natan, c., Love, D. C., Hanover, J. A. and Hochman

The Signal Peptide of Mouse Mammary Tumor Virus-Env: A Phosphoprotein Tumor Modulator, Molecular Cancer Research 2012.1077-1086

 Impact Factor:  4.380  Cited by 17  Rank: Q1

8. Sigalit Meker, Katrin Margulis-Goshen, Ester Weiss, Ori Braitbard, Jacob Hochman, Shlomo Magdassi, and Edit Y. Tshuva

Antitumor Activity of Nano-Formulated Phenolato Titanium (IV) Complexes

 Chem.Med.Chem.  2014 Mar 26,1294–1298.  

Impact Factor: 2.968  Cited by 14  Rank: Q1.

9. 9. Sigalit Meker, Ori Braitbard, Katrin Margulis-Goshen, Shlomo Magdassi, Jacob Hochman, Edit Tshuva 

Highly resistant anticancer titanium (IV) complexes and their mechanistic investigation using F-19 NMR‏

JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY, Aug 2014,19, S768-S769

IF: 2.968. Rank: Q1.

10. 10. Sigalit Meker, Ori Braitbard,Katrin Margulis-Goshen , Shlomo Magdassi , Jacob Hochman  and Edit Y. Tshuva

Highly Stable Tetra-Phenolato Titanium (IV) Agent Formulated into Nanoparticles Demonstrates Anti-Tumoral Activity and Selectivity   Molecules  2015, 20(10), 18526-18538

 Impact Factor: 2.416 Cited by 14  Rank: Q1.

11. 11. Lilia Reytman, Ori Braitbard, Jacob Hochman, and Edit Y. Tshuva,

 Highly Effective and Hydrolytically Stable Vanadium(V) Amino Phenolato Antitumor Agents

       Inorg. Chem. 55, 610 (2016)  ‎

       Impact Factor 4.820   Cited by 27 Rank: Q1.

12. Ori Braitbard, Maayan Roniger, Allan Bar-Sinai, Dana Rajchman, Tamar Gross, Hillel Abramovitch, Marco La Ferla, Sara Francesch, Francesca Lessi, Antonio Giuseppe Naccarato,  Chiara M. Mazzanti, Generoso Bevilacqua  and Jacob         Hochman.

 A New Immunization and Treatment Strategy for Mouse Mammary Tumor Virus (MMTV) Associated cancers.

Oncotarget, 2016 Feb 26. doi: 10.18632

 Impact Factor: 6.368  Cited by 7 Rank: Q1

13. Maya Miller, Ori Braitbard, Jacob Hochman and Edit Y. Tshuva. 

Insights into Molecular Mechanism of Action of Salan Titanium (IV) Complex with In vitro and In vivo Anticancer Activity.

 Journal of Inorganic Biochemistry. 2016 Apr 9. pii: S0162-0134(16)30089-7.

          impact factors: 3.444  Cited by 12 . Rank: Q2

14. 14. Sigalit Meker, Ori Braitbard, Matthew D. Hall, Jacob Hochman and Edit Y. Tshuva.

Specific Design of Titanium (IV) Phenolato Chelates Yields Stable and Accessible, Effective and Selective Anticancer Agents

Chemistry–A European Journal, 2016 Jul 11;22(29):9986-95.

            impact factors: 5.447   Cited by 22 Rank: Q1

15. 15. James S. Lawson, Chiara Mazzanti, Prospero Civita , Michele Menicagli , Christopher Ngan ,

          Noel J. Whitaker, Jacob Hochman, Ori Braitbard, Benafsha Yosufi , Wendy Glenn

Association of mouse mammary tumor virus with human breast cancer: histology, immunohistochemistry and polymerase chain reaction analyses

Frontiers in Oncology, 2018. 8: 141.

Impact Factor: 4.416  Cited by 6 Rank: Q1

16. Nitzan Ganot, Ori Braitbard, Asaad Jammal, Joseph Tam, Jacob Hochman, and Edit Y Tshuva. In Vivo Anticancer Activity of a Non-Toxic Inert Phenolato Ti Complex: High Efficacy on Solid Tumors Alone and Combined with Pt Drugs

ChemMedChem 2018, 13, 2290.

           Impact factor:3.009  Cited by 5 Rank: Q1.

17. 17. Maya Miller, Anna Mellul, Maya Braun, Dana Sherill-Rofe, Emiliano Cohen, Zohar Shpilt, Irene Unterman, Ori Braitbard, Jacob Hochman, Edit Y Tshuva, Yuval Tabach

Genomic analysis of phenolaTi-treated human breast cancer cells: Ti tackles the Endoplasmic Reticulum

iScience , 101262 2020

           Impact factor:5.8,   Rank: Q1.

18. Gilad Nahari, Ori Braitbard, Liraz Larush Jacob Hochman, and Edit Y. Tshuva

Effective Oral Administration of Antitumorigenic Nanoformulated Titanium Complex

ChemMedChem. 2020 Jul 12

           Impact factor:3.124  Rank: Q1

19. Ori Braitbard and Jacob Hochman

Maternal immunization impairs lymphoma growth and CNS metastasis in offspring

Under review

Peer-Reviewed Posters in Refereed Conference Proceedings

1. Multiple functions of the viral signal peptide(p14) in MMTV-associated breast cancer

Ori Braitbard and Jacob Hochman

EACR-AACR-ISCR Conference, International Convention Center (ICC) in Jerusalem on October 9-11, 2018.

2. Targeting the signal peptide in MMTV-associated breast cancer

Jacob Hochman and Ori Braitbard

Association for Cancer Immunotherapy (CIMT) ANNUAL MEETING, May 15-17, 2018, Mainz, Germany.

3. In vitro and In vivo activity of a new Anti-Cancer Phenolato Titanium (IV) Complex

Ori Braitbard ,Nitzan Ganot , Sigalit Meker, Jacob Hochman and Edit Y. Tshuva

EACR-AACR-SIC 2017 Special Conference ,24th – 27th June 2017, Florence, Italy

4. Signal peptide derived monoclonal antibodies impair mmtv-associated tumor growth

Ori Braitbard, Hillel Abramovitch and Jacob Hochman

Association for Cancer Immunotherapy (CIMT) ANNUAL MEETING, May 10-12, 2016, Mainz, Germany.

5. SIGNAL PEPTIDE-MEDIATED IMMUNE TARGETING OF MMTV-ASSOCIATED CANCERS

Jacob Hochman, Hillel Abramovitch and Ori Braitbard

The Keystone Symposia; Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology, Mar 19–23, 2016 | Fairmont Chateau Whistler | Whistler, British Columbia | Canada

6. Signal peptide –mediated immunization against Mouse Mammary Tumor Virus (MMTV)-associated tumors

Ori Braitbard, Tamar Gross, Maayan Roniger, Allan Bar-Sinai, Nira Hochman, Jacob Hochman, AACR- Tumor Immunology and Immunotherapy: A New Chapter
December 1-4, 2014, Orlando, FL

7. Highly Effective and Hydrolytically Stable Vanadium(V) Phenolato Antitumor Agents: Development, analysis and mechanistic investigation

Lilia Reytman, Ori Braitbard and Edit Y. Tshuva.

12th European Biological Inorganic Chemistry Conference, ZURICH, SWITZERLAND, August 24-28, 2014.

8. A Glimmpse Into Molecular of Phenolato Titaium(IV) Anticancer Commpexes.

 Maya Miller, Ori Braitbard, Yoav Smith, Jacob Hochman, Edit Y. Tshuva

12th European Biological Inorganic Chemistry Conference ZURICH, SWITZERLAND, August 24-28, 2014.

9. MOLECULAR MECHANISMS INVOLVED IN ANTI CANCER ACTIVITY OF NEWLY SYNTHESIZED TITANIUM (IV) COMPLEXES

Maya Miller, Ori Braitbard, Yoav Smith, Jacob Hochman, Edit Y. Tshuva.

THE SIXTH ANNUAL MEETING OF THE ISRAELI SOCIETY FOR CANCER       RESEARCH (ISCR), Haifa, Israel ,2014

10. Mechanism Investigation of Anti-cancer Titanium (IV) Complexes Using ¹⁹F NMR Detection.

Sigalit Meker, Ori braitbard, Katrin Margulis-Goshen, Shlomo Magdassi, Jacob Hochman, and Edit Y. Tshuva

The 79th Annual Meeting of the Israel Chemical Society. Tel Aviv, Israel.  February 2014

11. Using a Viral Signal Peptide as Vaccine: The Case for Mouse Mammary Tumor Virus.

Ori Braitbard, Maayan Roniger, Dana Raijman, Allan Bar-Sinai and Jacob Hochman.

The 13^th International Conference on Progress in Vaccination Against Cancer. Amsterdam, The Netherlands. October 2013

 

12. A signal peptide as a putative tool against MMTV-associated breast cancers

Ori Braitbard, Maayan Roniger, Dana Rajchman, Allan Bar-Sinai, Nira Hochman and Jacob Hochman, Advances in Breast Cancer Research: Genetics, Biology, and Clinical Applications San Diego, CA. Oct. 2013

13. ‘Salan’ Titanium (IV) Complexes: A New Class of Anti-Cancer Agents

Braitbard O., Meker, S., Stolarov M., Hochman J and Tshuva E. Y.

The 104^nd Annual Meeting of the American Association for Cancer Research, Washington, DC, April 2013

14. Highly Potent Anti-Cancer ‘Salan’ Titanium (IV) Complexes Structure - Function Relationship
15. Meker, O. Braitbard, C. M. Manna1, E. Weiss, E. Y. Tshuva and J. Hochman

The 103nd Annual Meeting of the American Association for Cancer Research, Chicago, Illinois, USA, April 2012.

15. A new class of Titanium compounds as anti-cancer drugs

Ori Braitbard, Cesar M. Manna, Esti Weiss, Jacob Hochman, Edit Y. Tshuva

The third annual meeting of the Israeli Society for Cancer Research, Jerusalem, Israel ,2011.

16. Cranberry juice constituents as an adjuvant for protein vaccination against malignant lymphoma

Jacob Hochman, Ori Braitbard, Maayan Roniger, Allan Bar-Sinai, Ervin I. Weiss, Nira Hochman

The 102nd Annual Meeting of the American Association for Cancer Research, Orlando, FL, 2011.

17. A Novel Human Hormone-Peptide NEROFE™ with Strong anti-Cancer Activity

Uziel Sandler, Orly Devary, Ori Braitbard, Joel Ohana, Gideon Kass, Yoram Devary

RECENT ADVANCES in CLINICAL MEDICINE , Cambridge, UK, 2010 156-161

The WSEAS Press publishes.   

18. A Novel Human Hormone-Peptide NEROFE Selectively Induces Apoptosis in Cancer Cells through the T1/ST2 Receptor

Uziel Sandler, Orly Devary, Ori Braitbard, Ariel M.Rubinstein, Zeev Y. Friedman, Yoram Devary

RECENT ADVANCES in CLINICAL MEDICINE 2010 162-167,The WSEAS Press  

20. A Novel Human Cytotoxic Cell Activation Factor with anti-Cancer Activity

Tamara Sandler, Ori Braitbard, Joel Ohana, Gideon Kass, Orly Devary

RECENT ADVANCES in CLINICAL MEDICINE Cambridge, UK, 2010 168-173

The WSEAS Press publishes. 

21. Reduction of multi-drug resistance from within live cells using the Mab C219 linked to (37-72) Tat

Ori Braitbard, Hans Wellhöner, Aryeh Weiss1, Axel Schulz, Knut Adermann, Allan Bar-Sinai and Jacob Hochman.  Inaugural meeting of the Israeli Society for Cancer, Tel-Aviv, Israel, 2009.

22. 22. Use of MMTV-p14 as a vaccine against MMTV-bearing tumors

Maayan Roniger, Ori Braitbard, Allan Bar-Sinai, Nira Hochman and Jacob Hochman

The 100^nd Annual Meeting of the American Association for Cancer Research, Denver, CO, 2009.

23. 23. Functional dissection of the Mouse Mammary Tumor Virus (MMTV) env-precursor leader sequence (p14) in cancer cells that harbor this virus. 

Dafna Feldman, Maayan Roniger, Allan Bar-Sinai, Ori Braitbard, Yonat Mordoch, Carmit Natan, Jacob Hochman.

AACR 99nd Annual Meeting, San Diego, California, 2008.

24. 24. A novel ligand - Thymus Expressed Apoptosis Factor induces apoptosis in cancer cells through T1/ST2 receptor

Uziel Sandler, Orly Devary, Ori Briatbard, Ariel M. Rubinstine, Zeev Y. Friedman, Yoram Devary JCT and ISK Ltd, Jerusalem, Israel, NCRI Cancer Conference, 2007

25. The Proteomatrix, a novel tool for cellular protein expression profiling:

       application to proteins involved in resistance to chemotherapy

       Student Lecture Competition, Ori Braitbard, Hava Glickstein, Janette Bishara-Shieban, Umberto Pace and Wilfred D. Stein, ISPP Annual Meeting, Maale HaChamisha Israel, 2005.

23. The Proteomatrix, a novel tool for cellular protein expression profiling: application to proteins involved in resistance to chemotherapy

Wilfred D. Stein, Ori Braitbard, Hava Glickstein, Janette Bishara, Umberto Pace. (2003), AACR 95^nd Annual Meeting, Washington, DC 2003.

In the underline meetings, I was the presenter of the results. 

 

•             Kamin Grant - The Office of the Chief Scientist of the Ministry of Industry.

Highly Active, Selective, Stable, and Accessible Anti-Cancer Complexes based on the Bio-Friendly Titanium(IV ) With Prof. Edit Tshuva ($200,000), 2014-2015.

• INTERNATIONAL UNION AGAINST CANCER Fellowship - ICRETT 1009/2004

       Host : Dr. Susan Bates - Molecular Therapeutics Section,

Nationa Cancer Institute,National Institutes of Health - Bethesda, USA.

2010—present             Research Associate –The Institute of Chemistry and the Dept. of Cell and Developmental Biology, Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Israel.

                                    Research interests:

1. Biological Applications of Ti(IV) Complexes (with Prof. Edit Y. Tshuva - Institute of Chemistry) .
2. 2. Developing novel approaches toward reversal of multi-drug resistance in cancer.
3. 3. Vaccination against breast cancer (with Jacob Hochman- Dept. of Cell and Developmental Biology).

2006- 2020                  Senior Scientist -  Immune System Key ltd.

1999-2006                   Researcher - MDR Tests ltd.